EcoVadis Platinum Level Achieved in 2026
We have renewed our EcoVadis assessment and achieved the Platinum level!
Press releases
June 3, 2024
BIOPHTA 6.5 million Euros Seed Funding
Paris, June 3, 2024
BIOPHTA, a preclinical biotech company developing a game-changing technology for the treatment of eye diseases, has just closed a € 6.5 million Seed round to bring its patented technology to clinical development.
This funding round was led by leading European VCs – UI Investissement (via the Pertinence Invest 2 Fund, advised by Mérieux Equity Partners), Elaia and GO Capital – as well as one major ophthalmology player, Unither Pharmaceuticals and HTL Biotechnology, the global leader in production and development of pharma grade biopolymers.
To see our most recent news,
follow us on LinkedIn
Read more
news from us
-
Press releases June 10, 20262026 National Biopharmaceutical Bioproduction Day
On June 4th, as part of the 3rd edition of the National Biopharmaceutical Bioproduction Day (#JNBB2026) organized by France BioLead, HTL Biotechnology was pleased to open the doors of its Javené facility to students and teachers who came to learn about careers in bioproduction.
-
Articles May 1, 2026Health & Safety Day 2026
At HTL Biotechnology, a culture of safety is deeply ingrained in our daily operations and guides all of our industrial practices. It is part of a clear goal: striving for zero accidents by placing prevention at the heart of our actions.
-
Articles April 13, 2026EcoVadis Platinum Level Achieved in 2026
We have renewed our EcoVadis assessment and achieved the Platinum level!